Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oral therapeutics for chronic diseases with high unmet need, including Type 2 diabetes, obesity, and pulmonary and cardiovascular diseases [9] - The company has a market capitalization of $5.60 billion and employs 163 people [5] - The net income for the trailing twelve months (TTM) is -$210.69 million, with a one-year price change of 212.55% as of January 12, 2026 [5] Recent Transactions - FMR LLC, a 10% owner of Structure Therapeutics, indirectly sold 52,356 shares for approximately $3.8 million on December 8, 2025 [2][3] - This sale represents the largest single open-market transaction for FMR LLC, significantly exceeding the recent median sell size of 21,997 shares [8] - Following the transaction, FMR LLC holds 471,207 shares indirectly, with a post-transaction value of approximately $33.92 million [3] Market Context - The shares were sold at a price of around $71.98 per share, which was higher than the market closing price of $69.98 on the same day [8] - Shortly after the sale, on December 11, 2025, Structure Therapeutics announced the closing of a public offering that raised approximately $748 million, indicating strong stakeholder support [12] Investment Considerations - Investors should note that FMR LLC purchased American Depositary Shares (ADS), which are fractional shares of ordinary shares offered on the U.S. stock market, allowing American investors to invest in foreign companies [10] - Holding ADS may incur occasional fees, typically ranging from 1 to 5 cents per share [11]